Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer

BACKGROUND: Epidermal growth factor receptor (EGFR) inhibitors, including cetuximab and panitumumab, are valuable therapeutics for colorectal cancer (CRC), but resistance to these inhibitors is common. The reason for such resistance is not well understood, which hampers development of better therape...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Lu, Bhattacharya, Arup, Li, Yun, Sexton, Sandra, Ling, Xiang, Li, Fengzhi, Zhang, Yuesheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161494/
https://www.ncbi.nlm.nih.gov/pubmed/35650607
http://dx.doi.org/10.1186/s13046-022-02389-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161494/
https://www.ncbi.nlm.nih.gov/pubmed/35650607
http://dx.doi.org/10.1186/s13046-022-02389-z

Ejemplares similares